IBDEI1MF ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27501,1,4,0)
 ;;=4^N02.4
 ;;^UTILITY(U,$J,358.3,27501,2)
 ;;=^5015515
 ;;^UTILITY(U,$J,358.3,27502,0)
 ;;=N02.5^^106^1363^78
 ;;^UTILITY(U,$J,358.3,27502,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27502,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,27502,1,4,0)
 ;;=4^N02.5
 ;;^UTILITY(U,$J,358.3,27502,2)
 ;;=^5015516
 ;;^UTILITY(U,$J,358.3,27503,0)
 ;;=N02.6^^106^1363^75
 ;;^UTILITY(U,$J,358.3,27503,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27503,1,3,0)
 ;;=3^Recurrent & perst hematur w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,27503,1,4,0)
 ;;=4^N02.6
 ;;^UTILITY(U,$J,358.3,27503,2)
 ;;=^5015517
 ;;^UTILITY(U,$J,358.3,27504,0)
 ;;=N02.7^^106^1363^76
 ;;^UTILITY(U,$J,358.3,27504,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27504,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,27504,1,4,0)
 ;;=4^N02.7
 ;;^UTILITY(U,$J,358.3,27504,2)
 ;;=^5015518
 ;;^UTILITY(U,$J,358.3,27505,0)
 ;;=N02.8^^106^1363^81
 ;;^UTILITY(U,$J,358.3,27505,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27505,1,3,0)
 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,27505,1,4,0)
 ;;=4^N02.8
 ;;^UTILITY(U,$J,358.3,27505,2)
 ;;=^5015519
 ;;^UTILITY(U,$J,358.3,27506,0)
 ;;=N02.9^^106^1363^82
 ;;^UTILITY(U,$J,358.3,27506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27506,1,3,0)
 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,27506,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,27506,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,27507,0)
 ;;=N03.0^^106^1363^18
 ;;^UTILITY(U,$J,358.3,27507,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27507,1,3,0)
 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,27507,1,4,0)
 ;;=4^N03.0
 ;;^UTILITY(U,$J,358.3,27507,2)
 ;;=^5015521
 ;;^UTILITY(U,$J,358.3,27508,0)
 ;;=N03.1^^106^1363^17
 ;;^UTILITY(U,$J,358.3,27508,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27508,1,3,0)
 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,27508,1,4,0)
 ;;=4^N03.1
 ;;^UTILITY(U,$J,358.3,27508,2)
 ;;=^5015522
 ;;^UTILITY(U,$J,358.3,27509,0)
 ;;=N03.2^^106^1363^14
 ;;^UTILITY(U,$J,358.3,27509,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27509,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,27509,1,4,0)
 ;;=4^N03.2
 ;;^UTILITY(U,$J,358.3,27509,2)
 ;;=^5015523
 ;;^UTILITY(U,$J,358.3,27510,0)
 ;;=N03.3^^106^1363^15
 ;;^UTILITY(U,$J,358.3,27510,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27510,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27510,1,4,0)
 ;;=4^N03.3
 ;;^UTILITY(U,$J,358.3,27510,2)
 ;;=^5015524
 ;;^UTILITY(U,$J,358.3,27511,0)
 ;;=N03.4^^106^1363^13
 ;;^UTILITY(U,$J,358.3,27511,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27511,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27511,1,4,0)
 ;;=4^N03.4
 ;;^UTILITY(U,$J,358.3,27511,2)
 ;;=^5015525
 ;;^UTILITY(U,$J,358.3,27512,0)
 ;;=N03.5^^106^1363^16
 ;;^UTILITY(U,$J,358.3,27512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27512,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,27512,1,4,0)
 ;;=4^N03.5
 ;;^UTILITY(U,$J,358.3,27512,2)
 ;;=^5015526
 ;;^UTILITY(U,$J,358.3,27513,0)
 ;;=N03.6^^106^1363^11
 ;;^UTILITY(U,$J,358.3,27513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27513,1,3,0)
 ;;=3^Chr nephritic syndrome w/ dense deposit disease
